Filing summary
Filing identity and period: The supplied filing is China Jo-Jo Drugstores, Inc.’s Form 20-F annual report for the fiscal year ended March 31, 2023—not a Ridgetech Inc. filing or a report for calendar 2022 Q4. The company reports under U.S. GAAP and operates primarily in China. The summary below follows the filing’s identity and reporting period.
Business context
China Jo-Jo operates retail pharmacies, an online pharmacy, pharmaceutical wholesale distribution and a traditional Chinese medicine herb-farming business. Its 114 Jiuzhou Grand Pharmacy stores were in Hangzhou; it also reported clinic services. The business is controlled substantially through contractual arrangements with Chinese variable interest entities (VIEs), rather than direct equity ownership. Fiscal 2023 revenue came 56.0% from retail drugstores, 21.8% online and 22.2% wholesale. Herb farming generated no revenue.
Financial performance and position
| Metric | FY ended March 31, 2023 | FY ended March 31, 2022 |
|---|---|---|
| Revenue | $148.8 million | $164.4 million |
| Gross profit / margin | $34.3 million / 23.0% | $36.5 million / 22.2% |
| Operating loss | $20.9 million | $2.7 million |
| Net loss | $21.1 million | $3.2 million |
| Operating cash flow | $(3.3) million | $(5.4) million |
| Investing cash flow | $(0.3) million | $(0.3) million |
| Financing cash flow | $2.4 million | $4.8 million |
Revenue declined 9.5%. Retail revenue slipped 1.0% in reported dollars (management said it increased 5.6% excluding currency effects); online revenue rose 7.2%, while wholesale revenue fell 33.8%. Wholesale contraction reflected the company’s decision to discontinue some low-margin sales and limited access to hospital customers. No herb harvest or sales were reported.
Gross margin improved, but higher expenses drove the larger loss. General and administrative expense rose 91.4% to $15.7 million, including a $7.58 million increase in the allowance for bad debts. The company also recorded $10.36 million of share-based compensation for 3.0 million restricted shares and a $2.32 million investment loss. Selling expense fell 5.5%, mainly reflecting lower rent, partly offset by higher online-platform fees. Basic loss per share was reported as $2.07, versus $0.92.
At March 31, 2023, cash and cash equivalents were $18.8 million; restricted cash was $12.8 million, bringing cash, cash equivalents and restricted cash to $31.6 million. Current assets of $64.5 million compared with current liabilities of $66.5 million, a $2.1 million working-capital deficit. Current liabilities included $29.3 million of bank acceptance notes payable, generally due within six to nine months and supported by restricted cash, and $5.1 million of current operating lease liabilities. Total operating lease liabilities were $12.9 million. The filing reports no bank loans outstanding at year-end. Operating cash remained negative.
Material changes and unusual items
- Net loss widened substantially from $3.2 million to $21.1 million, primarily amid higher bad-debt expense, share-based compensation and investment loss, alongside lower revenue.
- Shares outstanding at March 31, 2023 were 23,697,210, compared with 3,479,316 at March 31, 2022. The year included private placements and a registered direct offering, restricted-share awards and cashless warrant exercises; a 1-for-12 reverse split occurred in April 2022. The share-count increase is therefore important to assess alongside dilution and per-share figures.
- Management stated that cash, financing efforts and expected operating improvements should support operations for at least 12 months, but the filing says the losses, negative operating cash flow and working-capital deficit raise substantial doubt about the company’s ability to continue as a going concern.
- An April 2023 registered direct offering announced for approximately $7 million was terminated the following day. It did not provide the stated proceeds.
- The company reported an unqualified audit opinion on the financial statements. Management nevertheless concluded that disclosure controls and internal control over financial reporting were ineffective as of year-end, citing material weaknesses in U.S. GAAP expertise, supervisory review and timely reconciliations, including revenue and receivable collectability.
Outlook, risks and contingencies
Management cited additional medical-insurance reimbursement certificates for newer stores and efforts to improve store performance and financing access as potential support for operations. It did not provide numerical revenue, earnings or cash-flow guidance. It expects no significant near-term improvement in online gross margin and said wholesale growth may remain limited absent stronger agency or hospital access.
Key risks include the enforceability and regulatory treatment of the VIE arrangements; restrictions on moving cash from China and limits on dividends; China regulatory, data-security and cybersecurity changes; competition and medical-insurance budget controls; collection risk and bad-debt estimates; supplier and landlord deposits; foreign-exchange movements; and potential dilution or difficulty obtaining financing. The company reported $1.57 million in pharmacy landlord deposits and $0.14 million in supplier deposits in its risk disclosures. It also disclosed concentration in purchasing: four vendors represented 51.8% of purchases in FY2023, and one customer represented more than 10% of sales. Product-liability and malpractice coverage is not maintained, according to the risk disclosures. The filing reported no material pending legal proceedings.
VIE and China-related risks are material: substantially all operations are in China, and the listed parent relies on contractual arrangements rather than equity ownership to control key operating entities. The filing also discusses CSRC overseas-listing filing requirements effective March 31, 2023, and potential U.S. trading restrictions if PCAOB inspection access changes. It states that the auditor was inspected by the PCAOB in March 2023 and that the PCAOB reported full inspection access in China in 2022, while warning that future access is not assured.
Most important facts for investors to verify
- Confirm the issuer and period: the source is China Jo-Jo Drugstores’ FY2023 Form 20-F, not Ridgetech Inc.’s 2022 Q4 filing.
- Review the going-concern disclosure, near-term cash requirements, availability of credit and repayment timing for the $29.3 million of notes payable; distinguish unrestricted from restricted cash.
- Assess the $7.58 million increase in bad-debt allowance, the $14.1 million net trade receivables balance, subsequent collections disclosed through May 31, 2023, and the assumptions underlying expected credit losses.
- Reconcile the sharp increase in reported shares outstanding with offerings, restricted-share awards, reverse split and warrant exercises; assess resulting dilution and reported loss per share.
- Track whether management remediates the disclosed material weaknesses and whether future filings report effective controls.
- Evaluate the legal and practical enforceability of the VIE arrangements, cash-transfer restrictions, regulatory filing obligations and potential effects on U.S. listing and trading.